Drug Profile
CVS 2589
Alternative Names: CVS2589Latest Information Update: 12 Sep 2002
Price :
$50
*
At a glance
- Originator Dendreon San Diego LLC
- Class Antithrombotics
- Mechanism of Action Plasminogen activator inhibitors; Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Diabetic retinopathy
Most Recent Events
- 12 Sep 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 12 Sep 2002 Discontinued - Preclinical for Diabetic retinopathy in USA (unspecified route)
- 07 Apr 1999 Preclinical development for Diabetic retinopathy in USA (Unknown route)